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Objectives: Behavioral and psychological symptoms of dementia (BPSD) are preva-
lent in Alzheimer disease (AD) and are related to poor outcomes such as nursing
home placement. No study has examined the impact of individual BPSD on depen-
dence, a clinically important feature that reflects changing patient needs and their
effect on caregivers. The current study characterized independent cross-sectional and
longitudinal relationships between three BPSD (psychosis, depressed mood, and
agitation/aggression), cognition, and dependence to better understand the interplay
between these symptoms over time. Design: The Predictors Study measured changes
in BPSD, cognition, and dependence every 6 months in patients with AD. Cross-
sectional and longitudinal relationships between individual BPSD, cognition, and
dependence over 6 years were characterized by using multivariate latent growth
curve modeling. This approach characterizes independent changes in multiple
outcome measures over time. Setting: Four memory clinics in the United States and
Europe. Participants: A total of 517 patients with probable AD. Measurements:
Columbia University Scale for Psychopathology, modified MinieMental State Exam-
ination, and Dependence Scale. Results: Both psychosis and depressed mood at study
entry were associated with worse subsequent cognitive decline. Independent of
cognitive decline, initial psychosis was associated with worse subsequent increases in
dependence. Rates of increase in agitation/aggression separately correlated with
rates of declines in both cognition and independence. Conclusions: Although purely
observational, our findings support the poor prognosis associated with psychosis and
depression in AD. Results also show that agitation/aggression tracks declines in
cognition and independence independently over time. Targeted intervention for
individual BPSD, particularly psychosis, could have broad effects not only on patient
well-being but also on care costs and family burden. (Am J Geriatr Psychiatry 2015;
23:130e140)
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Behavioral and psychological symptoms ofdementia (BPSD) are prevalent in Alzheimer
disease (AD), occurring in 75% of patients.1 They
include symptoms such as agitation, depression, and
psychosis. BPSD accelerate poor outcomes in AD,
including nursing home placement. A recent review
found that in 21 of 36 studies, the presence of BPSD
predicted nursing home placement among individ-
uals with dementia.2 As is customary with research
on BPSD and family outcomes,3 most studies
combined all BPSD into a single category despite
evidence for disparate trajectories. A previous study
on a subset of the current sample followed up over
a shorter period of time suggests that agitation is
common and persistent in AD, whereas psychotic
symptoms are persistent but less common, and
depressed mood rarely persists.4
Results from studies examining the impact of
individual BPSD on nursing home placement have
been mixed. Agitation/aggression is repeatedly
associated with nursing home admission,5e7 but
results regarding psychosis and depression are
inconsistent.2,6,8,9 Unfortunately, many of these
studies featured relatively short follow-up, did not
control for other contributors to patient care needs
(e.g., cognitive decline), and/or focused on only one
BPSD. The current article sought to overcome these
limitations by examining the impact of individual
BPSD (i.e., psychosis, depressed mood, agitation/
aggression) on patient care needs over 6 years in
a sample of 517 patients with AD, controlling for
other factors that influence disease outcomes (e.g.,
education, cognitive decline).
In addition, the current study used a dynamic,
quantitative measure of patient dependence rather
than nursing home placement to index patient care
needs. Nursing home placement is influenced not only
by patient care needs but also by caregiver factors and
financial, cultural, and regional differences.2,10,11
Racial differences in formal care service utilization
exist,12 and the number of in-home services covered
by Medicaid differs according to geographic location.
Nursing home placement may not fully capture
a patient’s needs or the impact of these needs on the
family. Level of dependence correlates with dementia
severity,13 level of disability,14 home health aide use,15
longitudinal increases in medical and nonmedical
costs,16 overall resource utilization,14 increases in
caregiving time,17 and caregiver burden.14 Thus,
identifying and treating specific contributors to
dependence have the potential for wide-ranging
effects not only on patient quality of life but also on
care costs and family burden.
The goals of the current study were to characterize:
1) cross-sectional and longitudinal relationships
between individual BPSD (i.e., psychosis, depressed
mood, agitation/aggression) and cognition; and
2) cross-sectional and longitudinal relationships
between dependence and individual BPSD indepen-
dent of cognitive decline. Based on previous findings
of disparate courses of individual BPSD4 and effects of
BPSD on nursing home placement,2 we predicted that
worsening agitation/aggression and psychosis would
each relate to cognitive decline and increased depen-
dence, whereas depression would only be associated
with cognition and dependence cross-sectionally.
METHODS
Participants and Procedures
The sample included 517 patients with probable
AD enrolled in The Predictors Study, a multicenter
study of predictors of disease course in AD.18 Local
institutional review boards at all participating sites
approved the study. Written informed consent was
obtained directly from patients at study entry. All
patients had mild dementia at enrollment and were
deemed capable by a study physician of providing
informed consent. Patient assent was documented at
each subsequent visit in accordance with institutional
review board requirements. Characteristics of the
sample are shown in Table 1. Race and ethnicity were
determined by using patient and caregiver report
according to the format of the 2000 US Census.
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Study Design
Complete descriptions of study procedures have
been given previously.18,19 In brief, participants were
recruited in two waves beginning in 1989 (n ¼ 252) or
1998 (n ¼ 265) from clinics at four sites: Columbia
University Medical Center (n ¼ 208), Johns Hopkins
School of Medicine (n ¼ 147), Massachusetts General
Hospital (n¼ 124), and the Hôpital de la Salpêtrière in
Paris, France (n ¼ 38). Cross-site standardization was
ensured by requiring all raters to be certified at the
Columbia site. Diagnoses of probable AD were made
by using National Institute of Neurological and
Communicative Disorders and Stroke/Alzheimer’s
Disease and Related Disorders Association criteria20
at consensus conferences. At enrollment, all patients
were required to have mild dementia (i.e., score >29
on the 57-point modified MinieMental State Exami-
nation [mMMS; as described in the following section])
and at least one family member/caregiver available.
Exclusion criteria were non-AD dementia, parkin-
sonism, stroke, alcoholism, schizophrenia, schizo-
affective disorder, and electroconvulsive treatments.
Participantswereassessedevery6months forup to16
years. At least one follow-up assessment was available
for 97% of the study sample. On average, patients were
assessed on 10 occasions (standard deviation: 5.9). Only
data from the first 13 occasions (6 years) were included
in the study to maximize available data. Average attri-
tion rate between visits was 8.5%, and 176 participants
were assessed at the last visit. The study measures (as
described here) were administered on each occasion.
Measures
Global cognitive status was assessed by using the
mMMS.21 The mMMS includes all items from the
MinieMental State Examination22 as well as addi-
tional items assessing working memory, calculation,
recall of presidents, confrontation naming, repetition,
and visuoconstruction. Scores range from 0e57, with
higher scores indicating better cognition.
The main outcome measure was the Dependence
Scale (DS),11 a 13-item instrument administered to
caregivers. TheDSwas specifically designed to capture
the level of care required by a patient and more subtle
changes in service needs and family impact than
admission to a nursing home. Importantly, the DS is
not merely an alternative scale to assess function.
Rather, it assesses the impact of disabilityon thepatient
and family (e.g., does the patient need to be watched
when outside). Substantial development research has
demonstrated that the DS is related to cognition and
disease course independent of functional status. The
DS comprises 11 dichotomous items (e.g., “Does the
patient need to be watched or kept company when
awake?”) and two items on a 3-point Likert-type scale
(e.g., “Does the patient need reminders or advice to
manage chores, do shopping, cooking, play games or
handle money?”) Scores range from 0e15, with higher
scores indicating greater dependence. Psychometric
properties range from acceptable to excellent.11,23
Neuropsychiatric symptoms were assessed by
using the Columbia University Scale for Psychopa-
thology in Alzheimer’s Disease (CUSPAD),24 a semi-
structured interview conducted with a caregiver
assessing symptoms over the previous month. In the
current study, items assessing a similar construct
were summed to create the following subscores:
psychosis (i.e., delusions, hallucinations, illusions),
agitation/aggression (i.e., verbal outbursts, physical
threats and/or violence, agitation, restlessness), and
depressed mood (i.e., frequency of depressed mood).
Because the depression construct was measured with
a single item (range: 0e4), separate models treating
the depression variable as continuous versus cate-
gorical were run. Importantly, there were no differ-
ences in the patterns of associations between latent
variables in these models. Results presented here
represent the continuous variable models, and higher
scores indicate more severe symptoms.
Statistical Analysis
Descriptive statistics were used to characterize the
sample. Longitudinal data were analyzed in MPlus
TABLE 1. Patient Characteristics at Study Enrollment
N Mean or %
Standard
Deviation
Age 517 74.19 8.45
Education 517 13.72 3.62
Gender (% male) 517 43.1 e
Race (% white) 516 93.2 e
Ethnicity (% non-Hispanic) 514 95.2 e
Antidementia medications (% yes)a 450 31.1 e
Antidepressants (% yes) 428 21.3 e
Antipsychotic agents (% yes) 428 1.2 e
aOnly participants recruited during the second wave (after 1997)
reported taking antidementia medication at study entry.
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version 7 with latent growth curve (LGC), a special
case of structural equation modeling.25,26 Unlike
growth curve modeling using mixed models, LGC
accommodates multiple time-varying outcomes in
a multivariate framework. Multivariate LGC was
used to estimate associations between trajectories of
dependence, cognition, and BPSD. This analytic
approach controls for covariates measured at baseline
or throughout the study. Repeatedly measured vari-
ables are modeled both as independent outcomes and
as time-varying covariates. A primary advantage of
this approach is that longitudinal correlations
between the rates of change in multiple outcomes can
be estimated.
Missing data were managed with full information
maximum likelihood (FIML) using all available data
at each occasion. FIML accumulates and maximizes
case-wise likelihood functions computed by using all
available data for each participant. Monte Carlo
simulation has shown that FIML produces less biased
estimates than alternative methods.27 FIML does not
assume that data are missing completely at random
and can therefore accommodate missingness related
to previous scores. This feature of FIML is desirable
in longitudinal studies of cognition in AD because
participants lost to follow-up are often those who
were more impaired at earlier occasions.
The overall initial level (intercept) and amount of
change (slope) were key parameters. Additional
information regarding parameter estimation in
multivariate LGC is available elsewhere.25,28 Time
was parameterized in years from study entry. For all
outcomes, raw scores were used. Unstandardized
parameter estimates can be interpreted in terms of
the original scales. For example, linear slope esti-
mates reflect raw annual change on each outcome.
Model fit was assessed with the c2 test, the root mean
square error of approximation (RMSEA), the stan-
dardized root mean square residual (SRMSR), the
comparative fit index (CFI), and the Tucker-Lewis
index (TLI). Fit between nested models was
compared statistically by using the c2 test.
Model building proceeded in two stages. First,
trajectories of all five variables (DS, mMMS, and the
three CUSPAD subscores) were examined separately
with unconditional univariate models. Models esti-
mating only linear change were statistically
compared with those estimating linear and quadratic
change. Second, best-fitting univariate models were
combined into three conditional multivariate models,
in which the parameter estimates control for all
included variables. Each model simultaneously esti-
mated growth curves for three outcomes: DS,
mMMS, and a CUSPAD variable (i.e., psychosis,
depressed mood, agitation/aggression). Each model
also estimated the effects of four covariates measured
at baseline (i.e., age, gender, education level,
recruitment site) on all latent factors (i.e., intercepts,
linear slopes, quadratic slopes), and all unique
correlations between the latent factors, independent
of the covariates. In the multivariate models, associ-
ations between any two outcome variables (e.g.,
CUSPAD psychosis and dependence) are indepen-
dent of associations involving all other variables.
Covariates were centered to facilitate parameter
interpretation. Specifically, values of 0 corresponded
to age 74 years, 12 years of education, male gender,
and enrollment at the Columbia site.
RESULTS
Unconditional Univariate Models
Nested univariate models were built separately for
the five variables of interest. Slope estimates repre-
sent model-estimated raw, annual rates of change. In
models allowing only linear change, dependence
(slope estimate ¼ 1.03, standard error [SE] ¼ 0.03, z ¼
31.51, p <0.001), cognition (slope estimate ¼ "4.76,
SE ¼ 0.17, z ¼ "27.71, p <0.001), and agitation/
aggression (slope estimate ¼ 0.10, SE ¼ 0.02, z ¼ 6.02,
p <0.001) worsened over the study period. DS scores
worsened 1.03 points per year, mMMS scores wors-
ened 4.76 points per year, and CUSPAD agitation/
aggression scores worsened 0.10 point per year. In
contrast, depressed mood improved (slope
estimate ¼ "0.03, SE ¼ 0.01; z ¼ 2.87; p ¼ 0.004), and
psychotic symptoms did not change (slope
estimate ¼ "0.01; SE ¼ 0.02; z ¼ "0.24; p ¼ 0.81).
Allowingforcurvilinearchangesignificantly improved
modelfit for all variables: dependence (Dc2[4]¼"252.02,
p <0.001), cognition (Dc2[4] ¼ "576.30, p >0.001),
psychosis (Dc2[4] ¼ "103.75, p <0.001), agitation/
aggression (Dc2[4]¼ "155.18, p <0.001), and depressed
mood (Dc2[4] ¼ "60.32, p <0.001). Thus, models
including both linear and quadratic slopeswere retained.
Growth curves estimated according to the best-fitting
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univariatemodels are displayed in Figure 1. Dependence
(linear slope estimate ¼ 1.38; SE ¼ 0.08; z ¼ 17.45;
p<0.001), cognition (linear slope estimate¼ "5.24, SE¼
0.30, z ¼ "17.69, p <0.001), agitation/aggression (linear
slope estimate¼ 0.21, SE¼ 0.05, z¼ 4.13, p<0.001), and
psychotic symptoms (linear slope estimate ¼ 0.33, SE ¼
0.07, z¼ 4.45, p<0.001) worsened over the study period.
Psychotic symptoms subsequently improved (quadratic
slopeestimate¼"0.06, SE¼ 0.01, z¼"5.09,p<0.001), as
shown by the inverse U-shaped curve in Figure 1. In
contrast, depressed mood did not change (linear slope
estimate¼ 0.03, SE¼ 0.03, z¼ 1.04, p¼ 0.30).
Raw scores at each occasion are also shown in
Figure 1. It should be noted that scores at the
later occasions represent a highly select sample, as
lower-performing participants were more likely to be
lost to follow-up. As described earlier, FIML accom-
modates this pattern of missing data. For example,
the model-estimated trajectory of mMMS shown in
Figure 1 is not artificially elevated near the end of the
study period.
Conditional Multivariate Models
The best-fitting univariate models were combined
into threemultivariatemodels, eachofwhichestimated
growth curves forDS,mMMS, andaCUSPADsubscale
(psychosis, agitation/aggression, or depressed mood).
Each model also included four covariates (i.e., age,
gender, education, recruitment site). All three
FIGURE 1. Observed and model-estimated scores in the five univariate models. Y axes display full ranges for each scale so that
relative differences between symptom types can be appreciated. Errors bars represent standard deviations in sample
means at each visit. CUSPAD: Columbia Scale for Psychopathology in Alzheimer’s Disease; DS: Dependence Scale; mMMS:
modified MinieMental State Examination.
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models fit well: psychosis, CFI ¼ 0.88, TLI ¼ 0.88,
RMSEA ¼ 0.06, SRMSR ¼ 0.09; depressed mood,
CFI¼ 0.94, TLI¼ 0.94, RMSEA¼ 0.04, SRMSR¼ 0.06;
and agitation/aggression, CFI ¼ 0.92, TLI ¼ 0.92,
RMSEA ¼ 0.05, SRMSR ¼ 0.05.
Table 2 presents unstandardized parameter esti-
mates from each model. Initial levels are independent
of the other two outcomes. For example, the average
initial DS score for a 74-year-old male with 12 years
of education enrolled at the Columbia site was 5.2 in
all 3 models.
As shown, linear worsening over time was still
evident for dependence, cognition, and psychosis after
controlling for all variables. DS scores worsened 1.2
points per year, and mMMS scores worsened about
5.1 points per year. CUSPAD psychosis scores wors-
ened 0.5 point per year. This rate decelerated by 0.1
point per year, leading to eventual improvement.
Importantly, changes in psychotic symptoms were
independent of both cognitive decline and changes in
dependence.Changes in agitation/aggressionwereno
longer significant, contrasting with the 0.21 point of
TABLE 2. Unstandardized Parameter Estimates in the Conditional Multivariate Models for Three BPSD: Psychosis, Depressed Mood,
and Agitation/Aggression
Initial Level Rate of Change Change in the Rate of Change
Parameter SE z Parameter SE z Parameter SE z
Model 1: psychosis
Dependence Scale 5.215a 0.227 22.999 1.193a 0.163 7.314 "0.036 0.026 "1.397
mMMS 38.438a 0.566 67.922 "5.044a 0.605 "8.340 0.066 0.116 0.357
CUSPAD psychosis 0.917a 0.203 4.509 0.472b 0.159 2.965 "0.077b 0.025 "3.068
Model 2: depressed mood
Dependence Scale 5.204a 0.227 22.920 1.215a 0.163 7.438 "0.039 0.026 "1.511
mMMS 38.444a 0.566 67.885 "5.083a 0.607 "8.369 0.076 0.116 0.656
CUSPAD depressed mood 0.939a 0.089 10.554 "0.020 0.069 "0.292 "0.008 0.012 "0.657
Model 3: agitation/aggression
Dependence Scale 5.214a 0.226 23.073 1.209a 0.163 7.407 "0.038 0.026 "1.486
mMMS 38.449a 0.566 67.894 "5.118a 0.611 "8.380 0.085 0.118 0.720
CUSPAD agitation/aggression 1.002a 0.142 7.068 "0.001 0.104 "0.005 0.010 0.017 0.592
Notes: BPSD ¼ behavioral and psychological symptoms of dementia; CUSPAD ¼ Columbia Scale for Psychopathology in Alzheimer’s
Disease; mMMS ¼ modified MinieMental State Examination.
ap <0.001.
bp <0.01.
FIGURE 2. Schematic of significant associations between the latent variables in the three multivariate models. (A) Psychosis;
(B) Depressed mood; (C) Agitation/aggression. Effects are represented as correlation coefficients with the
corresponding z statistic used to determine significance. For simplicity, only associations involving the Columbia Scale
for Psychopathology in Alzheimer’s Disease variable are shown. Indicators and quadratic slopes are not shown.
ap <0.05; bp <0.001.
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annual worsening estimated by using the univariate
model. Thus, accounting for cognitive decline and
changes independence level rendered theworseningof
agitation/aggression negligible. Changes in depressed
mood remained nonsignificant in the multivariate
model.
Aim 1: BPSD and Cognition
Significant correlations between initial levels and
rates of change within the multivariate models are
shown in Figure 2. For clarity, correlations involving
quadratic slopes (i.e., acceleration or deceleration) are
not shown.
As shown in Figure 2, 5.3% of the variance in
initial cognitive impairmentwas explained by patients’
initial psychosis, with more psychotic symptoms asso-
ciated with worse cognition. Furthermore, patients’
initial psychosis explained 7.3% of the variance in
cognitive decline, with more initial psychotic symp-
toms associated with accelerated decline. Figure 3A
displays cognitive trajectories separately for partici-
pants with and without baseline psychotic symptoms.
As shown, patients with psychotic symptoms scored
worse on the mMMS at baseline, and their condition
declined faster over time. Rates of change in psychosis
and cognition were not correlated.
Initial depressed mood and cognition were not
correlated. Only 1.6% of the variance in cognitive
decline was explained by patients’ initial depressed
mood, with greater depressed mood associated with
accelerated cognitive decline. Figure 3B displays
cognitive trajectories separately for participants with
and without baseline depressed mood. As shown,
patients with depressed mood scored similarly on the
FIGURE 3. Estimated cognitive trajectories from the unconditional univariate models shown separately for participants with and
without (A) psychotic symptoms or (B) depressed mood at baseline. mMMS: modified MinieMental State Examination.
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mMMS initially but declined faster over time. Rates
of change in depressed mood and cognition were not
correlated.
Initial agitation/aggression and cognition were not
correlated. Initial agitation/aggression was not
related to cognitive decline. Six percent of the vari-
ance in cognitive decline was explained by rate of
change in agitation/aggression.
Aim 2: BPSD and Dependence
Approximately 17% of the variance in initial
dependence was explained by the patient’s initial
psychotic symptoms, with more symptoms associ-
ated with greater dependence. Initial psychosis also
explained 2.4% of the variance in the trajectory of
dependence levels, with more baseline psychotic
symptoms associated with accelerated increase in
dependence. Figure 4 displays dependence trajecto-
ries separately for participants with and without
baseline psychotic symptoms. As shown, patients
with psychotic symptoms had worse initial DS scores
with steeper increases over time. Rates of change in
psychosis and dependence were not correlated.
Initial depressed mood explained 8.6% of the
variance in initial dependence. There was no longi-
tudinal relationship between depressed mood and
dependence. Initial levels of agitation/aggression
and dependence were not correlated. Initial agita-
tion/aggression was not related to subsequent
changes in dependence. Almost 3% of the variance in
the rate of change in dependence was explained by
changes in agitation/aggression.
CONCLUSIONS
There were three main findings regarding cogni-
tive decline over 6 years in this study of 517 patients
with mild AD: 1) greater initial psychosis was asso-
ciated with worse baseline cognition; 2) greater initial
psychosis and depressed mood each predicted
accelerated cognitive decline; and 3) rates of change
in agitation/aggression and cognition were corre-
lated. There were three main findings regarding
dependence, independent of cognitive decline: 1)
higher initial psychosis and depressed mood were
associated with greater baseline dependence; 2)
higher initial psychosis predicted accelerated
increases in dependence over time; and 3) rates of
change in agitation/aggression and dependence
were correlated. Although the current study was
purely observational, this pattern of findings
provides new insights into the prognostic value of
psychosis and depressed mood in early AD and
suggests that agitation/aggression tracks closely
with declining cognition and dependence over time.
With regard to psychosis, initial levels were asso-
ciated not only with worse initial cognition and
dependence but also with more rapid disease
progression, as defined by accelerated worsening of
cognition and dependence. The magnitude of these
FIGURE 4. Estimated trajectories of dependence from the unconditional univariate model shown separately for participants with
and without psychotic symptoms at baseline.
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associations ranged from small to medium. For
example, baseline psychotic symptoms explained
>7% of the variance in cognitive decline. In addition
to this relationship, baseline psychotic symptoms
explained nearly one-fifth of the variance in initial
dependence. Findings regarding depressed mood
were smaller and more limited in that initial levels
were only associated with worse initial dependence
and accelerated cognitive decline.
These findings extend results from smaller samples
with more limited follow-up. For example, survival
analyses in a subset of the current cohort followed up
over 3 years showed that baseline psychosis pre-
dicted faster progression to a functional endpoint but
not nursing home placement.8 In independent
studies, psychosis and affective symptoms predicted
greater functional declines over 2 years.29e31 Simi-
larly, psychosis and depression predicted nursing
home placement in independent studies that did not
control for longitudinal changes in cognition.32,33 The
current study provides three novel observations
regarding psychosis and depression in early AD.
First, their prognostic value extends beyond func-
tional outcomes or nursing home placement to
patient care needs and their impact on the family (i.e.,
dependence). Second, the prognostic value of
psychosis is independent of longitudinal changes in
cognition. Third, psychosis has greater prognostic
value than depression.
Potential explanations for the prognostic value of
psychosis and depressed mood include “early
symptom” and “risk factor” hypotheses. In the early
symptom hypothesis, BPSD reflect more AD-related
neurodegenerative changes in the brain. For
example, AD patients with psychosis exhibited more
neocortical neurofibrillary tangles, but not plaques,
compared with patients without psychosis.34 Simi-
larly, AD patients with a lifetime history of major
depression have more hippocampal plaques and
tangles than patients with no history of depression.
Depression has also been associated with AD
pathology in older adults without AD.35 Recent
evidence from a community-based longitudinal
study supports the hypothesis that late-life depres-
sion accompanies cognitive decline and does not
precede it.36
In the risk factor hypothesis, BPSD lower brain
reserve capacity via non-AD pathology, which
reduces the brain’s ability to cope with AD
pathology. For example, AD psychosis is associated
with polymorphisms in multiple genes linked to
schizophrenia, including neuregulin-q and inter-
feron 1-beta.37,38 Resulting brain abnormalities may
increase susceptibility to AD-type neurodegeneration.
In the case of depression, dysregulation of the
hypothalamic-pituitary-adrenal axis, lowered levels of
brain-derived neurotrophic factor, and/or elevated
homocysteine levels may reduce resilience to AD
pathology.39 Although depression was related to
faster cognitive decline in this and other studies,
a recent study reported no effect of sertraline on
cognition in AD after 24 weeks.40 Future studies
should examine whether effective treatment of
depression or psychosis in AD influences cognitive
decline over longer periods. Whether such treatments
differentially affect cognitive domains should also be
explored, as cross-sectional studies suggest that mood
and psychotic symptoms are associated with different
profiles of cognitive impairment in AD.41
Unlike psychosis and depression, of which baseline
levels were markers of faster AD progression,
changes in agitation/aggression were longitudinally
associated with AD progression. Patients who
developed agitation/aggression also had faster
cognitive decline and loss of independence, suggest-
ing that agitation/aggression is consistently related
to declines in cognition and independence
throughout AD. Importantly, the longitudinal asso-
ciation between agitation/aggression and depen-
dence was independent of cognitive decline. It is
possible that increased agitation/aggression inter-
feres with engagement in cognitive tasks and
increases the need for supervision. Alternatively,
patients may react to both confusion and increased
care delivery with agitation/aggression.
In the multivariate model combining agitation/
aggression, cognition, and dependence, changes in
cognition and dependence fully accounted for the
worsening of agitation/aggression. In contrast,
changes in cognition and dependence remained
significant. This pattern of findings suggests that
improving cognition or dependence level has
a greater potential to alleviate agitation/aggression
than improving agitation/aggression has to recover
cognition or independence. Because changes in
psychotic symptoms were not eliminated in the
multivariate model, interventions to improve cogni-
tion or dependence may not alleviate psychotic
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symptoms. Future studies are needed to directly test
these hypotheses.
Due to modeling constraints, this study did not
include all variables associated with poor outcome in
AD. The included covariates were chosen because
they are prominent moderators of AD progression in
the extant literature and/or were associated with
outcomes in this sample. Previous reports from our
group have explored relationships between AD
progression and other variables, including APOE
genotype and motor signs.8,42e45
Strengths of the current study include the LGC
modeling, which estimated longitudinal relationships
between variables. Another major strength is the
multivariate nature of the models, which estimated
associations involving dependence independent of
cognitive decline. Models also used FIML to manage
missing data, which accommodates dropout related
to previous scores on outcomes. Finally, this study
examined individual BPSD separately to demonstrate
their unique predictive values.
Although the current study was purely observa-
tional, our finding that initial levels of psychosis and
depression predicted worse AD progression adds to
the literature on the prognostic value of individual
BPSD. In addition, the results indicate that agitation/
aggression tracks declines in both cognition and
independence independently throughout AD. Tar-
geted intervention for individual BPSD, particularly
psychosis, could have broad effects on patient well-
being, care costs, and family burden.
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